Crinetics Pharmaceuticals, Inc.·4

Mar 10, 4:51 PM ET

Hassard James 4

4 · Crinetics Pharmaceuticals, Inc. · Filed Mar 10, 2022

Insider Transaction Report

Form 4
Period: 2022-03-10
Hassard James
Chief Commercial Officer
Transactions
  • Award

    Stock Option (right to buy)

    2022-03-10+160,000160,000 total
    Exercise: $19.73Exp: 2032-03-09Common Stock (160,000 underlying)
Footnotes (1)
  • [F1]The option is exercisable as follows: 25% of the shares subject to the option vest on February 28, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION